[{"orgOrder":0,"company":"Immatics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Allogeneic T-cell therapies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Immatics","amount2":0.59999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"Immatics \/ GlaxoSmithKline","highestDevelopmentStatusID":"2","companyTruncated":"Immatics \/ GlaxoSmithKline"},{"orgOrder":0,"company":"Immatics","sponsor":"Arya Sciences Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"T cell immunotherapies","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immatics","amount2":0.25,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"","sponsorNew":"Immatics \/ Arya Sciences Acquisition Corp","highestDevelopmentStatusID":"4","companyTruncated":"Immatics \/ Arya Sciences Acquisition Corp"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"IMA202","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Not Applicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"IMA204","moa":"COL6A3","graph1":"Oncology","graph2":"Preclinical","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immatics \/ Not Applicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"IMA401","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Not Applicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"IMA101","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Not Applicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"IMA201","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Not Applicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"IMA402","moa":"T cell engaging receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immatics \/ Not Applicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"IMA401","moa":"MAGEA4\/8","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0.92000000000000004,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.92000000000000004,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IMA401","moa":"MAGEA4\/8","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Not Applicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"IMA203","moa":"TCR-T Cell","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Not Applicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Editas Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Gamma-delta T Cell Adoptive Cell Therapies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Immatics","highestDevelopmentStatusID":"2","companyTruncated":"Immatics \/ Immatics"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"IMA203","moa":"CD8 alpha beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Not Applicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"IMA402","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immatics \/ Not Applicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"IMA203","moa":"TCR-T Cell","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Jefferies"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"IMA203","moa":"TCR-T Cell","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Not Applicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"CAR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immatics","amount2":1.46,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.46,"dosageForm":"","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Immatics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"TCR-T-based Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immatics","amount2":0.51000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Immatics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"IMA203","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Not Applicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"TCR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"IMA402","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immatics \/ Not Applicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"IMA203","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":1.8200000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.8200000000000001,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Moderna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"IMA203","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Not Applicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"IMA203","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Not Applicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"IMA203","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Jefferies"},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"IMA203","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Immatics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Jefferies"},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"IMA203","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Immatics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Jefferies"},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"IMA203","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Not Applicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"IMA401","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Bristol Myers Squibb"}]
Find Clinical Drug Pipeline Developments & Deals by Immatics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
